IMMUNOe   Report issue

Academic/Hospital Phase 1 Phase 4
Founded: Centennial CO United States (1994)

Organization Overview

First Clinical Trial
2013
NCT02199925
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

IMMUNOe Health Centers | IMMUNOe International Clinical Research Centers | IMMUNOe Research Centers

Active Ingredients

Drugs in Phase 4 Trials (3)

C1 Esterase Inhibitor (Human) (Cinryze) (1 trial)

conestat alfa (Ruconest) (1 trial)

immune globulin (human) (Gamastan) (2 trials)

Drugs in Phase 1 Trials (1)

opt101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asperger Syndrome (Phase 4)

Autism Spectrum Disorder (Phase 4)

Autistic Disorder (Phase 4)

Common Variable Immunodeficiency (Phase 4)

Developmental Disabilities (Phase 4)

Disease (Phase 4)

Streptococcal Infections (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 4